New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
12:24 EDTRNAProsensa accelerated or conditional approvals likely, says Roth Capital
Roth Capital said its is "increasingly optimistic" that regulators won't focus on the outcome of Prosensa's disappointing phase 3 study for drisapersen and are likely to consider the totality of the data given the rare disease setting. The firm believes accelerated or conditional approvals for the drug are likely and it reiterates its Buy and $17 price target on the stock.
News For RNA From The Last 14 Days
Check below for free stories on RNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
08:25 EDTRNAProsensa weakness creates buying opportunity, says Oppenheimer
Subscribe for More Information
September 17, 2014
14:57 EDTRNAProsensa announces commencement of re-dosing of drisapersen
Subscribe for More Information
14:56 EDTRNAProsensa commences re-dosing of drisapersen in North America DMD patients

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use